Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



A Long Road Ahead for This Embattled Blood Thinner

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

The enormous rough diamond, called vorapaxar, that Merck  (NYSE: MRK  ) picked up in the Schering-Plough merger has been cut smaller and smaller during costly late-stage development. The first big setback was a pricey phase 3 trial that measured the prevention of clinical events in patients with acute coronary syndrome. In November 2011, the company announced that the drug did not meet its original endpoint. This failure basically buried the drug's chances of being a primary blood thinner for anyone at risk of heart attack.

Less than half a year later, Merck presented data from a phase 3 trial that measured vorapaxar's ability to reduce risk of cardiovascular events as a secondary prevention in patients with a previous heart attack or stroke. This trial did reach its endpoint, but there was a significant increase in intracranial hemorrhage among patients that had previously suffered a stroke. Again, the potential patient pool for vorapaxar became smaller.

A must win
The FDA intends to kick off the year with a series of three cardiovascular and renal drugs advisory committee meetings. On Jan. 15, they'll be discussing a New Drug Application, or NDA, from Merck for vorapaxar. The FDA accepted the NDA for standard review in July. Merck is seeking its approval for the secondary prevention of cardiovascular events in patients with a history of heart attack, but no history of stroke or ischemic attack.

The advisory committee meeting on the 15th could be the final nail in vorapaxar's very expensive coffin. A recent study conducted by the McKinsey Center for Government shows the regulator is strongly aligned with the opinions of its independent advisory committees. During NDA and BLA focused meetings that include voting, the FDA approved nearly 88% of drugs endorsed by the committee. Over the period from 2001-2010, only two of 14 drugs not endorsed by an advisory committee later won approval.

Some success
So far it doesn't look like much of a competitor. Although vorapaxar employs a different method of preventing clots than Plavix, it is hardly the wonder drug that Merck hoped it would be. The TRA-2P trial enrolled thousands of patients that had previously suffered heart attack or stroke. About 11.2% of those taking vorapaxar suffered cardiovascular death, myocardial infarction, stroke, or urgent coronary revascularization, versus 12.4% in the placebo group. The decrease of 1.2% might be statistically significant, but hardly exciting when combined with the documented risk of cranial hemorrhaging.

Questionable now equals excluded
Vorapaxar isn't the only blood thinner likely to experience pressure from cheap generic clopidogrel. Pharmacy benefit manager Express Scripts (NASDAQ: ESRX  ) is hammering away at higher cost drugs with incremental benefits. During the three months ended Sept. 30, the company raised its generic fill rate to 80.7% from 78% during the same period of the previous year. For 2014, the company updated its National Preferred Formulary to exclude 48 high-cost medications of questionable benefit with covered preferred alternatives. For Express Scripts, "preferred" usually means "inexpensive" generics.

The competition
The FDA approved generic versions of the Bristol-Myers Squibb blockbuster clopidogrel (Plavix) in May 2012. If vorapaxar does woo the committee, then later win approval, it will be competing for recent heart attack patients with an inexpensive option that physicians have had plenty of time to become comfortable with.

Luckily for Eli Lilly (NYSE: LLY  ) , its blood thinner Effient is on the Express Scripts formulary. U.S. sales of the clot preventer reached $339 million in 2012. During the first nine months of 2013, overall sales of Effient rose 12% on year.

Effient is marketed specifically to patients that have undergone an artery opening procedure, but not necessarily sufferers of a previous heart attack. If approved, vorapaxar is likely to compete with this platelet inhibitor for some patients. Like vorapaxar, Effient also has a history of bleeding complications.

Also escaping the exclusion list is Brilinta from AstraZeneca (NYSE: AZN  ) . This blood thinner is approved for the primary prevention of cardiovascular events in patients with acute coronary syndrome, not necessarily those with a history of heart attack. If approved, vorapaxar will likely compete with this platelet inhibitor, along with generic versions of Plavix.

AstraZeneca and Brilinta could take a serious turn for the worse in the near future. Both, the US Department of Justice and EU regulators are investigating the phase 3 trial, named PLATO, that pitted Brilinta against Plavix. Data from PLATO was used to show superiority over Plavix, and in turn to demand a much higher price. Drugmaker investigations are rarely worth getting excited about, but this one comes on the heels of a journal article published in the International Journal of Cardiology criticizing the reliability of trial data.

Take the shot
Pleasing the advisory committee on Jan. 15 would almost certainly cement a chance for vorapaxar to recoup some of the resources spent acquiring and developing the compound. The drug's different mechanism of action might be enough for payers and physicians to try it alongside existing treatments. Also, if the investigation of the PLATO trial turns out badly for AstraZeneca, it could play right into Merck's hand.

It's a long shot, but with both trials already paid for, it's certainly one worth taking. Let's just hope Merck doesn't initiate another vorapaxar trial if it doesn't win this time around.

The Fool's top stock for 2014
There's a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 18, 2015, at 12:16 PM, navychicano wrote:

    regarding vorapaxar.

    This 'new' prescription was assigned to me recently. After 2 painful weeks a discontinued taking vorapaxar with the agreement and acknowledgement of my cardiologist at the VA hospital.

    I'm a 66 yr old type 2 diabetic with both cardiac issues and peripheral artery issues. In 7yrs I've had 3 stents inserted in my heart arteries ( no issues since ) and 4 stents inserted in my right leg and one in my left leg . Also one stent in my artery to my left kidney.

    I have been suffering from RLS , most likely as a result of the conditions in my right leg.

    I am taking 2 Tramadol in the AM, 1 1/2 of a Codeine III and a Gabapentin at mid day, and 1 Gabapentin , 1 Ropinirole and 1/2 a Codeine III

    to sleep at night.

    Three weeks ago after my walking distance are become limited to about 50 yards , I again entered the Cathlab.

    They blew open my arteries and inserted 3 drug induced balloons.

    And prescribed Vorapaxar.

    My walking is back up to a mile +, but I started getting extreme mood wings. Depression, argumentative, sluggish, black stools, constants electrical feelings in my right leg, none of earlier medicines that I had been taking for my RLS seemed to work. The codeine III didn't work unless I increased the dosage , which left me like a zombie.

    I read up on Vorapaxar before I started taking I pill a day. It said only 2 % of their test patients had any severe side affects. I thought I was the perfect patient for Vorapaxar.

    It didn't work for me.

    My cardiologist agrees. He recently included 1 Plavix to my daily routine.

    All my negatives symptoms went away after 7 days after I discontinued the Vorapaxar.

    Steve Salaz

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2784028, ~/Articles/ArticleHandler.aspx, 8/28/2015 1:14:14 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Cory Renauer

Cory is a long-term minded analyst mainly focused on the biotechnology and pharmaceuticals. He genuinely enjoys cutting through the industry's complexities to help everyday investors make better decisions. You can contact Cory on Twitter @coryrenauer

Today's Market

updated Moments ago Sponsored by:
DOW 16,616.18 -38.59 -0.23%
S&P 500 1,983.14 -4.52 -0.23%
NASD 4,817.99 5.28 0.11%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/28/2015 12:58 PM
AZN $31.57 Down -0.04 -0.13%
AstraZeneca plc (A… CAPS Rating: ****
ESRX $84.27 Down -0.93 -1.09%
Express Scripts CAPS Rating: *****
LLY $83.64 Down -0.10 -0.12%
Eli Lilly & Co. CAPS Rating: ****
MRK $55.19 Up +0.24 +0.43%
Merck & Co., Inc. CAPS Rating: ****